Reliably evaluate the proarrhythmic and cardiotoxic liabilities of your compounds.
Figure 1.
A. Graph showing the peak hERG tail current (recorded at 37 °C) plotted against time for a representative cell treated with 1 and 10 μM ondansetron followed by 1 μM E-4031. The inset figure shows representative current traces in 0.1% DMSO, ondansetron and E-4031.
B. Graph showing the mean ± SD inhibition data (purple symbols), as well as individual inhibition values (grey symbols), plotted against concentration. The data were fitted with a Hill equation to yield the half-maximal inhibition concentration (IC50) and the 95% confidence bands (red dashed lines).
Early profiling does not require GLP hERG testing, however, it is crucial to follow optimal protocols to ensure accurate assessment of the half-maximal inhibitory concentration (IC50) of a compound against hERG. This includes using the optimal profiling platform to ensure accurate, high-quality assessment of potency, while maintaining ample throughput, turnaround time and cost effectiveness.
Reliably evaluate the proarrhythmic and cardiotoxic liabilities of your compounds.
Clear decision-making data for your project team is vital to ensure you avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.
Hear from industry experts, Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company) and Steve Jenkinson (Metrion).